- Home
- EIC vs VNDA Comparison
EIC vs VNDA Comparison
Compare EIC & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIC
- VNDA
- Stock Information
- Founded
- EIC N/A
- VNDA 2002
- Country
- EIC United States
- VNDA United States
- Employees
- EIC N/A
- VNDA N/A
- Industry
- EIC Finance/Investors Services
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- EIC Finance
- VNDA Health Care
- Exchange
- EIC Nasdaq
- VNDA Nasdaq
- Market Cap
- EIC 287.1M
- VNDA 270.0M
- IPO Year
- EIC 2019
- VNDA 2006
- Fundamental
- Price
- EIC $15.37
- VNDA $4.77
- Analyst Decision
- EIC
- VNDA Strong Buy
- Analyst Count
- EIC 0
- VNDA 2
- Target Price
- EIC N/A
- VNDA $15.50
- AVG Volume (30 Days)
- EIC 116.0K
- VNDA 704.2K
- Earning Date
- EIC 11-14-2023
- VNDA 02-05-2025
- Dividend Yield
- EIC 13.63%
- VNDA N/A
- EPS Growth
- EIC N/A
- VNDA N/A
- EPS
- EIC 0.80
- VNDA N/A
- Revenue
- EIC N/A
- VNDA $190,858,000.00
- Revenue This Year
- EIC N/A
- VNDA $5.60
- Revenue Next Year
- EIC N/A
- VNDA $42.85
- P/E Ratio
- EIC $20.31
- VNDA N/A
- Revenue Growth
- EIC N/A
- VNDA N/A
- 52 Week Low
- EIC $13.00
- VNDA $3.46
- 52 Week High
- EIC $16.48
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- EIC 35.79
- VNDA 42.69
- Support Level
- EIC $15.11
- VNDA $4.49
- Resistance Level
- EIC $15.35
- VNDA $4.81
- Average True Range (ATR)
- EIC 0.16
- VNDA 0.18
- MACD
- EIC -0.04
- VNDA -0.03
- Stochastic Oscillator
- EIC 20.83
- VNDA 25.71
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.